American Academy of Ophthalmology Meeting

American Academy of Ophthalmology Meeting

October 30, 2018
1 min read

Anatomic results maintained at end of brolucizumab studies

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

CHICAGO — Brolucizumab maintained non-inferiority to aflibercept regarding best corrected visual acuity change at week 96, which was the end of the HAWK and HARRIER trials, according to a speaker.

In both trials, the primary endpoint of non-inferiority to aflibercept 2 mg (Regeneron) was reached at week 48.

“This was achieved whilst over 75% of brolucizumab 6 mg patients (Novartis) who completed week 48 on a q12 week interval remained on that same q12 week interval until week 96,” Pravin U. Dugel, MD, reported at Retina Subspecialty Day preceding the American Academy of Ophthalmology annual meeting.

In both studies, brolucizumab achieved superior reduction in central subfield thickness compared with aflibercept, and the difference was maintained to week 96, he said. As well, fewer patients on brolucizumab had intraretinal fluid, subretinal fluid or subretinal pigment epithelium fluid throughout the trials.

“The findings of the HAWK and HARRIER are consistent with the phase 2 OSPREY study. Here there was a 36-week head-to-head q8 week matched comparison vs. aflibercept that showed numerically greater central subfield thickness reduction of brolucizumab vs. aflibercept, greater resolution of subretinal fluid and intraretinal fluid of brolucizumab vs. aflibercept, and similar ocular and safety profiles,” Dugel said. – by Patricia Nale, ELS



Dugel PU. Brolucizumab for neovascular AMD: the 2-year HAWK and HARRIER results. Presented at: AAO Subspecialty Day; Oct. 26-27, 2018; Chicago.

Disclosure: Dugel reports he is a consultant for Alcon and Novartis.